A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in
conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will
allow exposure to MCI-196 for up to 52 weeks